CAR-T Cell Therapy as Bridge to Allogeneic Stem Cell Transplantation in a Heavily Pre-treated Follicular Lymphoma Patient (EHA-EBMT-CART 2026) - Feb 22, 2026 - Pres time: Feb 12, 2026; 07:55 PM - 08:55 PM; Location: CAR-T Theatre & Exhibition Area; In person; "The patient experienced disease relapse six years after first-line chemoimmunotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP) followed by rituximab maintenance...She subsequently received high-dose chemoimmunotherapy with rituximab, oxaliplatin, dexamethasone, cytarabine (R-DHAOx) achieving complete remission, then consolidation with autologous stem cell transplantation...A chemo-free approach was attempted with lenalidomide–rituximab (R²) and later mosunetuzumab, but disease progression was observed in both cases, with documented loss of CD20 expression after T-cell-engaging therapy. Further salvage treatments with chemotherapy (vincristine, gemcitabine) and immunotherapy (polatuzumab-vedotin) failed to achieve a response, and the disease evolved into a highly aggressive phase characterized by B symptoms, multiple lymphadenopathies, rapidly progressive splenomegaly, leukemic involvement, and hemophagocytic..."
CAR T-Cell Therapy • Clinical • IO biomarker • Acute Graft versus Host Disease • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Gastrointestinal Disorder • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Hemophagocytic lymphohistiocytosis • Hypotension • Immunology • Lymphoma • Non-Hodgkin's Lymphoma • Rare Diseases • Transplantation • CD20
|
|
E. Amaducci 1; M. Clerico 2; I. Dogliotti 2; S. Ragaini 1; C. Consoli 1; M. Pironti 1; G. Mallia 1; C. Marinucci 1; S. Giorgi 1; V. Zorzetto 1; F. Ferrando 1; A. Martin 1; M. D'Agostino 1,2; M. Dicataldo 2; L. Giaccone 1,2; S. Ferrero 3,2; B. Bruno 1,2; F. Cavallo 1,2
|